Please assess the completion status of the following clinical trial:

Trial Title: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥18 years~* Patients with suspected or known Coronary artery disease who are undergoing invasive cardiac catheterization~* Patients with at least one significant stenosis (diameter stenosis \>50%) with Fractional Flow Reserve (FFR) \>0.80 and meeting two of the following criteria:~  1. MLA(minimal luminal area)\<4mm2~ 2. Plaque burden\>70%~ 3. Large lipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy), defined as MaxLCBI4mm\>315~ 4. TCFA(thin-cap fibroatheroma) defined as fibrous cap thickness \<65 μm and arc \>90° on optical coherence tomography (OCT) or ≥10% confluent necrotic core with \>30° abutting the lumen in three consecutive slices on Virtual-histology intravascular ultrasound (VH-IVUS)~* Eligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular Scaffold or Everolimus Eluting Stent~* Reference vessel diameter 2.75-4.0~* Lesion length ≤ 40mm~* Willing and able to provide informed written consent~Exclusion Criteria:~* Patients for whom the preferred treatment is CABG(Coronary artery bypass grafting)~* Patients with stented lesions~* Patients with bypass graft lesions~* Patients with three or more target lesions~* Patients with two target lesions in the same coronary territory~* Patients with heavily calcified or angulated lesions~* Patients with bifurcation lesions requiring 2 stenting technique~* Patients with contraindications to or planned discontinuation of dual antiplatelet therapy within 1 year~* Patients with life expectancy \<2 years~* Patients with planned cardiac or major noncardiac surgery~* Woman who are breastfeeding, pregnant or planning to become pregnant during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Coronary intervention (Type: EXPERIMENTAL): bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) +Optimal Medical Treatment
- Optimal Medical Treatment (Type: ACTIVE_COMPARATOR): Optimal Medical Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).